Aptoll molecules for the treatment of ischemic stroke and intracranial hemorrhages
AssigneeMerck Patent GmbH
InventorsMacarena Hernández Jiménez, David Segarra De La Peña, María Eugenia Zarabozo Leal
Life of this patent
Estimating the term…
Abstract
The APRIL study showed that the infusion of ApTOLL 0.2 mg/kg (SEQ ID NO: 1) in combination with endovascular treatment in selected stroke patients is safe and reduces the mortality at 90 days. ApTOLL has demonstrated that limit the phenomena of intracranial hemorrhages and reperfusion damage that may occur after recanalization, and also improves early neurological impairment and long term disability. ApTOLL molecules are provided for use in reducing the risk of intracranial or secondary hemorrhages, in reducing the neurological damage and in improving the neurological recovery after an acute ischemic stroke in a subject.
Claims15
An aptamer with SEQ ID NO:
- 1 for use in reducing the risk of intracranial hemorrhages after an acute ischemic stroke in a subject, wherein the aptamer is administered after the acute ischemic stroke at a dose of at least about 0.2 mg/kg, and wherein the administration of the aptamer reduces the risk of intracranial hemorrhages in at least about a 14% with respect to a subject not treated with the aptamer.
An aptamer with SEQ ID NO:
- 1 for use in improving the neurological recovery after an acute ischemic stroke in a subject, wherein the improvement of neurological recovery is mediated by a reduction of the risk of intracranial hemorrhages, wherein the aptamer is administered after the acute ischemic stroke at a dose of at least about 0.2 mg/kg, and wherein the aptamer:
- (i) reduces the NIHSS score, and
- (ii) reduces the mRS score to 0-2,
- with respect to a subject not treated with the aptamer.
Dependencies are inferred from the claim text.